By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Trodelvy/Keytruda patients had 11.2 months progression-free survival vs 7.8 months for chemotherapy/Keytruda ASCO says Trodelvy/Keytruda likely to become standard of care Patients still being ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer – First Pivotal ...

First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC – – Early Trend in Improvement in ...